Women - reduce your Cardio Vascular Risk by 20% with Semaglutide [Lancet]

Hey everyone — a research paper just landed in the Lancet that's directly relevant to a huge share of our patients, so I wanted to get a summary out while it's fresh.

The finding: semaglutide reduces the risk of major cardiovascular events — heart attacks, strokes — by 20% in people who are overweight or obese with existing heart issues. And critically: this held even in people WITHOUT diabetes.

Read that again. This isn't a diabetes benefit. This is heart protection in its own right, going beyond what the weight loss alone would explain.

Here's why I'm flagging it specifically for women: heart disease flies under the radar for women in a way it doesn't for men. The symptoms present differently, the risk gets under-recognized by everyone (including, frankly, the medical system), and it remains the leading cause of death for women — ahead of every cancer combined. A medication that quietly cuts major cardiac events by a fifth is a very big deal for a group whose risk is chronically underestimated.

It's exciting to watch the science keep landing where our clinic experience already points. Our patients come in for weight loss, and the wins they rack up go way past the scale — blood pressure, energy, mobility, and now, per the Lancet, measurably protected hearts.

If heart disease runs in your family and you've been on the fence about doing something for your weight — this research is worth a conversation with us.

(original paper linked at the bottom, as always)

-Daryl

Book a FREE consult now <- Click There!

www.pnwmedicalgroup.com

Puyallup: 253-340-2270

Federal Way: 253-363-8877